A blood-based multi-pathway biomarker assay for early detection and staging of Alzheimer's disease across ethnic groups
© 2024 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association..
INTRODUCTION: Existing blood-based biomarkers for Alzheimer's disease (AD) mainly focus on its pathological features. However, studies on blood-based biomarkers associated with other biological processes for a comprehensive evaluation of AD status are limited.
METHODS: We developed a blood-based, multiplex biomarker assay for AD that measures the levels of 21 proteins involved in multiple biological pathways. We evaluated the assay's performance for classifying AD and indicating AD-related endophenotypes in three independent cohorts from Chinese or European-descent populations.
RESULTS: The 21-protein assay accurately classified AD (area under the receiver operating characteristic curve [AUC] = 0.9407 to 0.9867) and mild cognitive impairment (MCI; AUC = 0.8434 to 0.8945) while also indicating brain amyloid pathology. Moreover, the assay simultaneously evaluated the changes of five biological processes in individuals and revealed the ethnic-specific dysregulations of biological processes upon AD progression.
DISCUSSION: This study demonstrated the utility of a blood-based, multi-pathway biomarker assay for early screening and staging of AD, providing insights for patient stratification and precision medicine.
HIGHLIGHTS: The authors developed a blood-based biomarker assay for Alzheimer's disease. The 21-protein assay classifies AD/MCI and indicates brain amyloid pathology. The 21-protein assay can simultaneously assess activities of five biological processes. Ethnic-specific dysregulations of biological processes in AD were revealed.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Alzheimer's & dementia : the journal of the Alzheimer's Association - 20(2024), 3 vom: 01. März, Seite 2000-2015 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jiang, Yuanbing [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Alzheimer's disease |
|---|
| Anmerkungen: |
Date Completed 18.03.2024 Date Revised 03.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/alz.13676 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366739581 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366739581 | ||
| 003 | DE-627 | ||
| 005 | 20240403235208.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240108s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/alz.13676 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1363.xml |
| 035 | |a (DE-627)NLM366739581 | ||
| 035 | |a (NLM)38183344 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jiang, Yuanbing |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A blood-based multi-pathway biomarker assay for early detection and staging of Alzheimer's disease across ethnic groups |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.03.2024 | ||
| 500 | |a Date Revised 03.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association. | ||
| 520 | |a INTRODUCTION: Existing blood-based biomarkers for Alzheimer's disease (AD) mainly focus on its pathological features. However, studies on blood-based biomarkers associated with other biological processes for a comprehensive evaluation of AD status are limited | ||
| 520 | |a METHODS: We developed a blood-based, multiplex biomarker assay for AD that measures the levels of 21 proteins involved in multiple biological pathways. We evaluated the assay's performance for classifying AD and indicating AD-related endophenotypes in three independent cohorts from Chinese or European-descent populations | ||
| 520 | |a RESULTS: The 21-protein assay accurately classified AD (area under the receiver operating characteristic curve [AUC] = 0.9407 to 0.9867) and mild cognitive impairment (MCI; AUC = 0.8434 to 0.8945) while also indicating brain amyloid pathology. Moreover, the assay simultaneously evaluated the changes of five biological processes in individuals and revealed the ethnic-specific dysregulations of biological processes upon AD progression | ||
| 520 | |a DISCUSSION: This study demonstrated the utility of a blood-based, multi-pathway biomarker assay for early screening and staging of AD, providing insights for patient stratification and precision medicine | ||
| 520 | |a HIGHLIGHTS: The authors developed a blood-based biomarker assay for Alzheimer's disease. The 21-protein assay classifies AD/MCI and indicates brain amyloid pathology. The 21-protein assay can simultaneously assess activities of five biological processes. Ethnic-specific dysregulations of biological processes in AD were revealed | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Alzheimer's disease | |
| 650 | 4 | |a amyloid pathology | |
| 650 | 4 | |a blood biomarkers | |
| 650 | 4 | |a disease staging | |
| 650 | 4 | |a early detection | |
| 650 | 4 | |a patient stratification | |
| 650 | 4 | |a precision medicine | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Amyloid beta-Peptides |2 NLM | |
| 650 | 7 | |a tau Proteins |2 NLM | |
| 700 | 1 | |a Uhm, Hyebin |e verfasserin |4 aut | |
| 700 | 1 | |a Ip, Fanny C |e verfasserin |4 aut | |
| 700 | 1 | |a Ouyang, Li |e verfasserin |4 aut | |
| 700 | 1 | |a Lo, Ronnie M N |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Elaine Y L |e verfasserin |4 aut | |
| 700 | 1 | |a Cao, Xiaoyun |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, Clara M C |e verfasserin |4 aut | |
| 700 | 1 | |a Law, Brian C H |e verfasserin |4 aut | |
| 700 | 1 | |a Ortiz-Romero, Paula |e verfasserin |4 aut | |
| 700 | 1 | |a Puig-Pijoan, Albert |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández-Lebrero, Aida |e verfasserin |4 aut | |
| 700 | 1 | |a Contador, José |e verfasserin |4 aut | |
| 700 | 1 | |a Mok, Kin Y |e verfasserin |4 aut | |
| 700 | 1 | |a Hardy, John |e verfasserin |4 aut | |
| 700 | 1 | |a Kwok, Timothy C Y |e verfasserin |4 aut | |
| 700 | 1 | |a Mok, Vincent C T |e verfasserin |4 aut | |
| 700 | 1 | |a Suárez-Calvet, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Zetterberg, Henrik |e verfasserin |4 aut | |
| 700 | 1 | |a Fu, Amy K Y |e verfasserin |4 aut | |
| 700 | 1 | |a Ip, Nancy Y |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Alzheimer's & dementia : the journal of the Alzheimer's Association |d 2005 |g 20(2024), 3 vom: 01. März, Seite 2000-2015 |w (DE-627)NLM168942356 |x 1552-5279 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2024 |g number:3 |g day:01 |g month:03 |g pages:2000-2015 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/alz.13676 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2024 |e 3 |b 01 |c 03 |h 2000-2015 | ||